Diffuse Large B-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Diffuse Large B-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-21Clinical Trial Update: AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL [Phase 3]
Phase 3 trial evaluating AZD0486 as first-line therapy for elderly or unfit patients with diffuse large B-cell lymphoma is currently recruit…
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL [Phase 3]
Clinical trial update for a Phase 3 study of Brentuximab Vedotin with Lenalidomide and Rituximab in relapsed/refractory Diffuse Large B-Cell…
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers [Phase 1]
This document outlines an ongoing Phase 1 trial evaluating NKX019, an allogeneic CAR NK cell therapy, in adults with B-cell cancers includin…
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma [Phase 1]
Phase 1 clinical trial update evaluating zanubrutinib in combination with sonrotoclax for relapsed or refractory B-cell non-Hodgkin lymphoma…
-
CLINICAL_TRIALS trial_result · 2026-04-20Clinical Trial Update: CAR-T Combined With ASCT in the Treatment of Relapsed/Refractory Large B-cell Lymphoma With High-risk Factors. [Phase 2]
A Phase 2 clinical trial is evaluating CAR-T cell therapy combined with autologous stem cell transplantation for high-risk relapsed/refracto…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) [Phase 2, Phase 3]
A phase 2/3 clinical trial evaluating Zilovertamab Vedotin (MK-2140) with standard of care in relapsed or refractory diffuse large B-cell ly…
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma [Phase 2]
A Phase 2 clinical trial is evaluating acalabrutinib in combination with DA-EPOCH-R or R-CHOP for patients with untreated diffuse large B-ce…
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma [Phase 1, Phase 2]
This document outlines a Phase 1/2 clinical trial (ViPOR) evaluating a combination of venetoclax, ibrutinib, prednisone, obinutuzumab, and l…
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011) [Phase 2]
This Phase 2 trial compares zilovertamab vedotin plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) against Polatuzumab v…
-
CLINICAL_TRIALS trial_result · 2026-04-20Clinical Trial Update: Serplulimab, Chidamide, and Rituximab Followed by Sequential R-CHOP for Newly Diagnosed Elderly MYC/BCL2 Double-Expressor DLBCL [Phase 2]
A Phase 2 trial is evaluating serplulimab, chidamide, and rituximab followed by sequential R-CHOP in newly diagnosed elderly patients with M…
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma [Phase 2]
Phase 2 clinical trial update for a novel combination therapy in relapsed or refractory aggressive B-cell lymphoma (diffuse large B-cell lym…
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: Study of Out of Specification for Tisagenlecleucel [Phase 3]
This document reports a Phase 3 clinical trial update for tisagenlecleucel (Kymriah) addressing an out-of-specification issue, for indicatio…
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: Phase I Clinical Study on the Safety and Efficacy of CY-219 CAR-T Cell Injection in the Treatment of Relapsed/Refractory B-Cell Lymphoma [Phase 1]
Phase I clinical trial evaluating CY-219 CAR-T cell therapy for relapsed/refractory B-cell lymphoma; not yet recruiting.
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing
A clinical trial update describing leukapheresis collection for manufacturing CAR or adoptive cell therapies, with enrollment by invitation …
-
CLINICAL_TRIALS trial_result · 2026-04-17Clinical Trial Update: Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL [Phase 1, Phase 2]
Phase I/II clinical trial update describing the study of Rapcabtagene Autoleucel in chronic lymphocytic leukemia, small lymphocytic lymphoma…
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers [Phase 1]
This is a Phase 1 clinical trial update for LY4584180 in adults with previously treated blood cancers, including Non-Hodgkin lymphoma, diffu…
-
CLINICAL_TRIALS trial_result · 2026-04-17Clinical Trial Update: External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL [Phase 1]
This Clinical Trials update describes a Phase 1 study evaluating external beam radiotherapy followed by a bispecific antibody therapy for re…
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: Study of CTO1681 for the Prevention and Treatment of CRS in DLBCL Patients Receiving CAR T-Cell Therapy [Phase 1, Phase 2]
A clinical trial update indicates CTO1681 is being studied in Phase 1/2 to prevent or treat cytokine release syndrome in patients with diffu…
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma [Phase 1, Phase 2]
A Phase 1/2 study evaluating Rondecabtagene Autoleucel for aggressive large B-cell lymphoma in patients with relapsed or refractory Non-Hodg…
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia [Phase 2]
A Phase 2 clinical trial evaluating ascorbic acid with chemotherapy for relapsed/refractory lymphoma, clonal cytopenia of undetermined signi…
-
CLINICAL_TRIALS trial_result · 2026-04-16Clinical Trial Update: Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma [Phase 2]
Phase 2 study of polatuzumab vedotin with the R-GDP regimen in relapsed/refractory diffuse large B-cell lymphoma was terminated, with result…
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL [Phase 1, Phase 2]
This clinical trial update describes sequential IOMAB-CAR-T followed by CAR-T cell therapy for relapsed/refractory diffuse large B-cell lymp…
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study [Phase 2]
Phase 2 clinical trial evaluating rituximab, lenalidomide, acalabrutinib, and tafasitamab (alone and with chemotherapy) for newly diagnosed …
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma [Phase 2]
A Phase 2 clinical trial evaluating pomalidomide combined with an anti-PD-1 antibody and selinexor (PPS) in relapsed/refractory primary cent…
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma [Phase 1, Phase 2]
A Phase 1/2 clinical trial update describes autologous stem cell transplant followed by polatuzumab vedotin for patients with various B-cell…